Clinical trials on the effectiveness of PROVENGE (sipuleucel-T) have shown that the medication can help men with certain types of prostate cancer to live longer. In these studies, men who were given PROVENGE lived an average of 4.1 months longer than those who received a placebo. However, the prostate cancer progressed just as quickly in men given PROVENGE as it did in men given the placebo.
Is PROVENGE Effective in Treating Prostate Cancer?PROVENGE® (sipuleucel-T) is a prescription medicine approved for the treatment of prostate cancer. The effectiveness of this medicine has been evaluated in clinical trials. Based on these studies, PROVENGE appears to be effective at helping men with certain types of prostate cancer to live longer.
More Information on PROVENGE Clinical Trials
PROVENGE has been studied in randomized, double-blind, placebo-controlled trials (the gold standard for clinical trials). In these studies, one group of people is randomly selected to receive the active medication (PROVENGE), while another group is randomly selected to receive a control medication (a placebo that does not contain the active ingredient).
A study is considered "double-blind" when the study investigators and the people enrolled in the study do not know which people are in each group, or are blinded to the group assignments.
The PROVENGE clinical studies enrolled men with metastatic prostate cancer (cancer that had spread to other areas of the body, such as the bone) that was resistant to hormone therapy. All of the men in the studies had either no prostate cancer symptoms or only minimal symptoms.